Merck & Co., Inc.
5 new studies at major medical meeting further demonstrate clinical experience for JANUVIA
Published in Medical Letter on the CDC and FDA, September 28th, 2008
Study data show longer term efficacy and safety and tolerability profile of JANUVIA up to two years
JANUVIA and metformin as initial combination therapy demonstrated significant glucose-lowering efficacy over two years Pooled analysis of 6,139 patients showed JANUVIA was generally well tolerated in clinical trials, up to two years in duration Investigational study of the addition of JANUVIA to the combination of metformin and rosiglitazone significantly improved blood sugar control 52-week study of Japanese patients with an investigational...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Emory University
As head and neck cancer risks evolve, more treatment options emerge - Research
Help from herpes? Coinfection induces acyclovir to inhibit HIV - HIV/AIDS
New HIV/AIDS study findings reported from E. Seminari and co-authors - Life Sciences
Research from Stanford University provides new data about life sciences - MiCardia Corporation
MiCardia Corporation Receives US FDA Market Clearance for Dynaplasty Annuloplasty Devices - Regulatory Actions
New regulatory actions study findings reported from C.A. Stockl and co-authors - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
